The VEGF IRESes are differentially susceptible to translation inhibition by miR-16

  1. Zeïneb S. Karaa1,2,
  2. Jason S. Iacovoni1,3,
  3. Amandine Bastide1,2,
  4. Eric Lacazette1,2,
  5. Christian Touriol1,2,4 and
  6. Hervé Prats1,2,4
  1. 1Institut National de la Santé et de la Recherche Médicale (INSERM), U858, F-31432 Toulouse, France
  2. 2Institut de Médecine Moléculaire de Rangueil, Université de Toulouse (UPS), IFR31, F-31432, Toulouse, France
  3. 3Institut Fédératif de Recherche (IFR31), Institut Louis Bugnard, CHU Rangueil, BP 84225, 31432 Toulouse cedex 4, France
  1. 4 These authors contributed equally to this work.

Abstract

Experiments with EMCV (Encephalomyocarditis virus) internal ribosome entry sites (IRESes) have shown that microRNAs (miRs) are unable to inhibit IRES driven translation. However, it is accepted that miRs can inhibit translation through multiple mechanisms, only some of which require interaction with the 5′ cap structure. In this report, we first validate the targeting of miR-16 to a predicted binding site in the VEGF 3′UTR. We developed a series of experiments to ascertain whether or not miR-16 can inhibit translation of transcripts driven by either of the VEGF IRESes. Our results indicate that cellular IRESes can be classified as both sensitive and insensitive to miR control. While VEGF IRES-A activity was not altered by miR-16 targeting to the 3′UTR, IRES-B was susceptible to miR-16 inhibition. Taken together with previous results that show that IRES-B selectively translates the CUG initiated VEGF-121 isoform, we can conclude that the existence of two differentially susceptible IRESes in the VEGF 5′UTR leads to even more complex regulatory control of VEGF isoform production. This study demonstrates for the first time the inhibition of cellular IRES driven translation by a miR.

Keywords:

Keywords

Footnotes

  • Reprint requests to: Hervé Prats, Institut National de la Santé et de la Recherche Médicale (INSERM), U858, CHU Rangueil, BP 84225, 31432 Toulouse cedex 4, France; e-mail: herve.prats{at}inserm.fr; fax: +33 561 32 21 41.

  • Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.1301109.

    • Received July 31, 2008.
    • Accepted November 7, 2008.
  • Freely available online through the open access option.

| Table of Contents
OPEN ACCESS ARTICLE